Do analysts rate GELS or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, GELS or ABVC?

Gelteq has higher earnings, but lower revenue than ABVC BioPharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 68.23 -$4.30M N/A N/A ABVC BioPharma $510K 58.63 -$7.91M -$0.40 N/A

Is GELS or ABVC more profitable?

Gelteq's return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A ABVC BioPharma N/A -62.46% -39.99%

Do analysts recommend GELS or VIRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, GELS or VIRI?

Gelteq has higher revenue and earnings than Virios Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 68.23 -$4.30M N/A N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is GELS or VIRI more profitable?

Gelteq's return on equity of 0.00% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Virios Therapeutics N/A -130.33% -115.00%

Do analysts prefer GELS or KYNB?

Kyntra Bio has a consensus price target of $32.50, indicating a potential upside of 362.30%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Kyntra Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has higher valuation and earnings, GELS or KYNB?

Kyntra Bio has higher revenue and earnings than Gelteq. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Gelteq $110K 68.23 -$4.30M N/A N/A Kyntra Bio $6.44M 4.42 $183.45M $40.46 0.17

Is GELS or KYNB more profitable?

Kyntra Bio has a net margin of 2,199.13% compared to Gelteq's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Gelteq N/A N/A N/A Kyntra Bio 2,199.13% N/A -36.71%

Do analysts rate ACTU or GELS?

Actuate Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 1,383.05%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Actuate Therapeutics is more favorable than Gelteq. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Actuate Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, ACTU or GELS?

Gelteq has higher revenue and earnings than Actuate Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Actuate Therapeutics N/A N/A -$22.23M -$0.97 N/A Gelteq $110K 68.23 -$4.30M N/A N/A

Is ACTU or GELS more profitable?

Gelteq's return on equity of 0.00% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Gelteq N/A N/A N/A

Do analysts prefer BGM or GELS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Gelteq 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, BGM or GELS?

Gelteq has lower revenue, but higher earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $37.92M 0.74 -$19.94M N/A N/A Gelteq $110K 68.23 -$4.30M N/A N/A

Is BGM or GELS more profitable?

Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Gelteq N/A N/A N/A

Gelteq (GELS) Competitors

$0.70 -0.04 (-5.68%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$0.68 -0.02 (-2.97%)

As of 07/24/2026 07:13 PM Eastern

Compare

GELS vs. ABVC, VIRI, KYNB, ACTU, and BGM

Should you buy Gelteq stock or one of its competitors? MarketBeat compares Gelteq with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gelteq include ABVC BioPharma (ABVC), Virios Therapeutics (VIRI), Kyntra Bio (KYNB), Actuate Therapeutics (ACTU), and BGM Group (BGM). These companies are all part of the "pharmaceutical products" industry.

How does Gelteq compare to ABVC BioPharma?

Gelteq (NASDAQ:GELS) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability.

Gelteq has a beta of -0.55, meaning that its stock price is 155% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.54, meaning that its stock price is 46% less volatile than the broader market.

11.4% of ABVC BioPharma shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Gelteq and Gelteq both had 2 articles in the media. Gelteq's average media sentiment score of 1.43 beat ABVC BioPharma's score of 0.93 indicating that Gelteq is being referred to more favorably in the media.

Company	Overall Sentiment
Gelteq	Positive
ABVC BioPharma	Positive

Gelteq's return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
ABVC BioPharma	N/A	-62.46%	-39.99%

Gelteq has higher earnings, but lower revenue than ABVC BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	68.23	-$4.30M	N/A	N/A
ABVC BioPharma	$510K	58.63	-$7.91M	-$0.40	N/A

Summary

Gelteq beats ABVC BioPharma on 5 of the 9 factors compared between the two stocks.

How does Gelteq compare to Virios Therapeutics?

Gelteq (NASDAQ:GELS) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, earnings, institutional ownership, analyst recommendations, valuation, profitability, risk and media sentiment.

In the previous week, Gelteq had 2 more articles in the media than Virios Therapeutics. MarketBeat recorded 2 mentions for Gelteq and 0 mentions for Virios Therapeutics. Gelteq's average media sentiment score of 1.43 beat Virios Therapeutics' score of 0.00 indicating that Gelteq is being referred to more favorably in the media.

Company	Overall Sentiment
Gelteq	Positive
Virios Therapeutics	Neutral

Gelteq's return on equity of 0.00% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Virios Therapeutics	N/A	-130.33%	-115.00%

Gelteq has a beta of -0.55, indicating that its share price is 155% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the broader market.

9.1% of Virios Therapeutics shares are held by institutional investors. 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gelteq has higher revenue and earnings than Virios Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	68.23	-$4.30M	N/A	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Gelteq beats Virios Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Gelteq compare to Kyntra Bio?

Gelteq (NASDAQ:GELS) and Kyntra Bio (NASDAQ:KYNB) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, earnings, dividends, institutional ownership, profitability, analyst recommendations, risk and media sentiment.

Kyntra Bio has a consensus price target of $32.50, indicating a potential upside of 362.30%. Given Kyntra Bio's stronger consensus rating and higher probable upside, analysts plainly believe Kyntra Bio is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Gelteq had 1 more articles in the media than Kyntra Bio. MarketBeat recorded 2 mentions for Gelteq and 1 mentions for Kyntra Bio. Kyntra Bio's average media sentiment score of 1.87 beat Gelteq's score of 1.43 indicating that Kyntra Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Gelteq	Positive
Kyntra Bio	Very Positive

Kyntra Bio has higher revenue and earnings than Gelteq.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gelteq	$110K	68.23	-$4.30M	N/A	N/A
Kyntra Bio	$6.44M	4.42	$183.45M	$40.46	0.17

Kyntra Bio has a net margin of 2,199.13% compared to Gelteq's net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Gelteq	N/A	N/A	N/A
Kyntra Bio	2,199.13%	N/A	-36.71%

Gelteq has a beta of -0.55, indicating that its stock price is 155% less volatile than the broader market. Comparatively, Kyntra Bio has a beta of 0.96, indicating that its stock price is 4% less volatile than the broader market.

72.7% of Kyntra Bio shares are owned by institutional investors. 4.2% of Kyntra Bio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Kyntra Bio beats Gelteq on 11 of the 14 factors compared between the two stocks.

How does Gelteq compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, media sentiment, profitability, valuation, earnings, risk and institutional ownership.

In the previous week, Gelteq had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for Gelteq and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.89 beat Gelteq's score of 1.43 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Very Positive
Gelteq	Positive

Gelteq's return on equity of 0.00% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Gelteq	N/A	N/A	N/A

Actuate Therapeutics presently has a consensus target price of $17.50, suggesting a potential upside of 1,383.05%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Actuate Therapeutics is more favorable than Gelteq.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Gelteq has higher revenue and earnings than Actuate Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Gelteq	$110K	68.23	-$4.30M	N/A	N/A

Actuate Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Gelteq has a beta of -0.55, meaning that its share price is 155% less volatile than the broader market.

Summary

Actuate Therapeutics and Gelteq tied by winning 5 of the 10 factors compared between the two stocks.

How does Gelteq compare to BGM Group?

BGM Group (NASDAQ:BGM) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, earnings, risk, media sentiment and valuation.

Gelteq has lower revenue, but higher earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$37.92M	0.74	-$19.94M	N/A	N/A
Gelteq	$110K	68.23	-$4.30M	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Gelteq	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, BGM Group had 1 more articles in the media than Gelteq. MarketBeat recorded 3 mentions for BGM Group and 2 mentions for Gelteq. Gelteq's average media sentiment score of 1.43 beat BGM Group's score of 0.30 indicating that Gelteq is being referred to more favorably in the news media.

Company	Overall Sentiment
BGM Group	Neutral
Gelteq	Positive

BGM Group has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, Gelteq has a beta of -0.55, meaning that its stock price is 155% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Gelteq	N/A	N/A	N/A

Summary

BGM Group and Gelteq tied by winning 3 of the 6 factors compared between the two stocks.

Get Gelteq News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GELS vs. The Competition

Export

Metric	Gelteq	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.51M	$3.67B	$7.07B	$12.22B
Dividend Yield	N/A	2.18%	2.67%	9.42%
P/E Ratio	N/A	11.18	22.28	21.35
Price / Sales	68.23	298.37	523.79	89.76
Price / Cash	N/A	59.51	26.39	46.67
Price / Book	0.65	7.89	10.30	6.08
Net Income	-$4.30M	$23.81M	$3.60B	$331.70M
7 Day Performance	15.62%	-3.82%	-1.27%	-0.63%
1 Month Performance	10.71%	-4.45%	-1.67%	-3.04%
1 Year Performance	-63.31%	33.01%	18.25%	13.30%

Gelteq Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GELS Gelteq	1.2191 of 5 stars	$0.70 -5.7%	N/A	-63.3%	$7.51M	$110K	N/A	N/A	Positive News Short Interest Decrease
ABVC ABVC BioPharma	0.505 of 5 stars	$1.15 -4.2%	N/A	-61.8%	$29.90M	$510K	N/A	30
VIRI Virios Therapeutics	N/A	$1.50 -2.6%	N/A	-68.3%	$28.89M	N/A	N/A	5
KYNB Kyntra Bio	4.1364 of 5 stars	$7.03 -0.6%	$32.50 +362.3%	N/A	$28.46M	$6.44M	N/A	570	Positive News
ACTU Actuate Therapeutics	2.6404 of 5 stars	$1.18 -6.3%	$17.50 +1,383.1%	-83.7%	$28.23M	N/A	N/A	10	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GELS) was last updated on 7/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gelteq (GELS) Competitors

GELS vs. ABVC, VIRI, KYNB, ACTU, and BGM

How does Gelteq compare to ABVC BioPharma?

Summary

How does Gelteq compare to Virios Therapeutics?

Summary

How does Gelteq compare to Kyntra Bio?

Summary

How does Gelteq compare to Actuate Therapeutics?

Summary

How does Gelteq compare to BGM Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gelteq (GELS) Competitors

GELS vs. ABVC, VIRI, KYNB, ACTU, and BGM

How does Gelteq compare to ABVC BioPharma?

Which has more volatility and risk, GELS or ABVC?

Do insiders and institutionals have more ownership in GELS or ABVC?

Do analysts rate GELS or ABVC?

Does the media favor GELS or ABVC?

Is GELS or ABVC more profitable?

Which has stronger earnings & valuation, GELS or ABVC?

Summary

How does Gelteq compare to Virios Therapeutics?

Does the media prefer GELS or VIRI?

Is GELS or VIRI more profitable?

Which has more risk and volatility, GELS or VIRI?

Do institutionals & insiders believe in GELS or VIRI?

Which has stronger valuation & earnings, GELS or VIRI?

Do analysts recommend GELS or VIRI?

Summary

How does Gelteq compare to Kyntra Bio?

Do analysts prefer GELS or KYNB?

Does the media prefer GELS or KYNB?

Which has higher valuation and earnings, GELS or KYNB?

Is GELS or KYNB more profitable?

Which has more volatility & risk, GELS or KYNB?

Do institutionals & insiders believe in GELS or KYNB?

Summary

How does Gelteq compare to Actuate Therapeutics?

Does the media refer more to ACTU or GELS?

Is ACTU or GELS more profitable?

Do analysts rate ACTU or GELS?

Which has stronger valuation & earnings, ACTU or GELS?

Which has more volatility and risk, ACTU or GELS?

Summary

How does Gelteq compare to BGM Group?

Which has better earnings & valuation, BGM or GELS?

Do analysts prefer BGM or GELS?

Does the media prefer BGM or GELS?

Which has more risk and volatility, BGM or GELS?

Is BGM or GELS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GELS vs. The Competition

Gelteq Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools